Want to see ECIA full AI Analyst Report?
Encision (ECIA) AI Stock Analysis
Encision
(Other OTC:ECIA)
The score is held down primarily by weak financial performance (declining revenue, widening losses, negative cash flow, and rising leverage). Technicals add additional risk given the strong downtrend versus all major moving averages, while valuation provides limited support due to a loss-driven negative P/E and no dividend yield data.
Encision (ECIA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $194.12K
- Dividend Yield
- ―
- Average Volume (3M)
- 11.01K
- Price to Earnings (P/E)
- -11.5
- Beta (1Y)
- 25.58
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 23
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Encision Business Overview & Revenue Model
Company Description
Encision Inc. (ECIA), established in 1991 and headquartered in Boulder, Colorado, operates as a medical device firm specializing in the development, manufacturing, and commercialization of proprietary surgical instruments for the U.S. market. The com...
Encision Financial Statement Overview
Summary
Weak fundamentals drive a low score: revenue declined again (~-8%), profitability is negative (net margin ~-12%), and both operating cash flow and free cash flow are negative. Balance-sheet risk has increased as leverage rose (debt ~1.19x equity) while equity declined, despite gross margin remaining relatively solid (~47%).
Income Statement
28NegativeBalance Sheet
40NegativeCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.39M | 5.78M | 6.56M | 6.59M | 7.35M | 7.67M |
| Gross Profit | 1.12M | 2.71M | 3.51M | 3.14M | 4.03M | 3.79M |
| EBITDA | 53.67K | -542.60K | -95.08K | -544.20K | -217.51K | 55.10K |
| Net Income | -16.94K | -719.08K | -220.20K | -691.78K | -366.00K | 463.34K |
Balance Sheet | ||||||
| Total Assets | 3.45M | 3.70M | 3.67M | 3.81M | 4.13M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 275.43K | 245.11K | 257.43K | 42.51K | 189.00K | 950.00K |
| Total Debt | 1.42M | 1.70M | 1.31M | 1.33M | 1.08M | 1.15M |
| Total Liabilities | 1.96M | 2.27M | 2.02M | 1.98M | 1.64M | 2.05M |
| Stockholders Equity | 1.50M | 1.43M | 1.65M | 1.83M | 2.50M | 2.75M |
Cash Flow | ||||||
| Free Cash Flow | 29.69K | -427.64K | -134.97K | 107.57K | -1.04M | -480.00K |
| Operating Cash Flow | 29.69K | -384.42K | -54.95K | 144.39K | -861.00K | -444.00K |
| Investing Cash Flow | -4,712 | -45.62K | -80.03K | -36.82K | -183.00K | -36.00K |
| Financing Cash Flow | 5,342 | 417.72K | 349.90K | -254.02K | 284.00K | -44.00K |
Encision Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ECIA, the sentiment is Negative. The current price of 0.01 is above the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.04, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 31.71 is Neutral, neither overbought nor oversold. The STOCH value of -3.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ECIA.
Encision Risk Analysis
Encision disclosed 14 risk factors in its most recent earnings report. Encision reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksEncision Peers Comparison
Overall Rating
WOK43Neutral- ECIA40Underperform
GCTK39Underperform
LUCY38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| WOK | 43Neutral | $4.47M | -0.00 | -18.55% | ― | ― | ― |
| ECIA | 40Underperform | $194.12K | -11.50 | -1.15% | ― | ― | ― |
| GCTK | 39Underperform | $959.14K | -0.00 | -2135.52% | ― | ― | 99.51% |
| LUCY | 38Underperform | $7.24M | -0.61 | -88.90% | ― | 72.50% | 58.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ECIA | Encision Inc. | 0.01 | -0.19 | -94.50% | |
| GCTK | Glucotrack, Inc. | 0.81 | -192.99 | -99.58% | |
| LUCY | Innovative Eyewear, Inc. | 0.83 | -0.88 | -51.46% | |
| WOK | WORK Medical Technology Group LTD | 1.00 | -32799.00 | -100.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026